Announcement on Subsidiary MWN117 Injection Obtaining Drug Clinical Trial Approval Notice

Lepu Medical Technology (Beijing) Co., Ltd.·August 17, 2026·2 pages

✨ AI Summary

Lepu (Beijing) Medical Device Co., Ltd. announces its subsidiary Shanghai Minwei Biotechnology received approval for the MWN117 injection clinical trial for obesity and overweight. MWN117 is an siRNA drug targeting INHBE, with global IP. Pre-clinical studies show efficacy and safety. The company is advancing development, acknowledging risks.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Code: 300003

Securities Abbreviation: Lepu Medical

Announcement No.: 2026-053

Lepu (Beijing) Medical Device Co., Ltd.

Announcement on Subsidiary MWN117 Injection Obtaining Drug Clinical Trial Approval Notice

The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.

Lepu (Beijing) Medical Device Co., Ltd. (hereinafter referred to as the "Company") learned today that its holding subsidiary, Shanghai Minwei Biotechnology Co., Ltd. (hereinafter referred to as "Shanghai Minwei Biotechnology"), has received the "Drug Clinical Trial Approval Notice" (Notice No.: 2026LP02426) issued by the National Medical Products Administration, approving Shanghai Minwei Biotechnology's application for clinical trials of MWN117 injection. The relevant situation is hereby announced as follows:

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.